Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-50
SponsorCharite University, Berlin, Germany
About this trial
The XCVD study investigates the influence of sex hormones on the composition of the gut microbiome and the possible emergence of cardiovascular risk factors. It will follow 200 healthy transgender individuals for five years during their hormone replacement therapy (HRT) and analyze them for the possible emergence of cardiovascular risk factors in relation to changes in the gut microbiome, metabolome, and immunome. We would also like to phenotype cardiovascular disease.
Eligibility criteria
Qualifiers
Age 18-50
Language requirements: German, English
Previous gender hormone replacement therapy (HRT).
Ability to give consent and written consent to participate.
Disqualifiers
Diseases or functional disorders that, in the opinion of the study physician, preclude participation in the study.
Incapacity or other circumstances that do not allow study participants to fully understand the nature, significance and scope of this study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1Experimental and Clinical Research Center, Clinical Research Unit13125, Berlin Germany
Sponsors and collaborators
Charite University, Berlin, Germany
Lead sponsor
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Collaborator
Source ClinicalTrials.gov